Type I and Ⅱ Cardiorenal Syndrome-related Biomarkers
10.13422/j.cnki.syfjx.20191328
- VernacularTitle: Ⅰ型和Ⅱ型心肾综合征相关生物标志物研究进展
- Author:
Meng-meng WANG
1
;
Dong-xue QIAO
1
;
Xin GAO
1
;
Bo YANG
1
;
Mao-juan GUO
2
;
Hong-tao YANG
1
Author Information
1. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine(TCM), Tianjin 300000, China
2. Tianjin University of TCM, Tianjin 300000, China
- Publication Type:Research Article
- Keywords:
cardiorenal syndrome;
pathogenesis;
biomarkers;
renal tubular injury;
cell cycle arrest inducing factor
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(20):222-228
- CountryChina
- Language:Chinese
-
Abstract:
The physiology and pathology of the heart and kidney are interdependent and interact with each other, and dysfunction of any one of them causes dysfunction of the other, namely cardiorenal syndrome, in which type I and type Ⅱ have the highest incidence rate and are the commonest in clinic. Traditional Chinese medicine has a long history of treating the cardiorenal syndrome. It believes that the disease is located in the heart and kidney, and Wenyang Yiqi, Huoxue Lishui and other methods shall be adopted to effectively improve the heart and kidney function of patients. However,the pathogenesis of cardiorenal syndrome is complicated, and the clinical manifestations are diverse, which makes it difficult to diagnose and treat in the early stage, and causes missing of the best intervention timing and a poor prognosis. Biomarkers play a vital role in predicting the occurrence and development of cardiorenal syndrome. Therefore, efforts shall be made to look for biomarkers with better specificity and sensitivity, accurately evaluate physiological and pathological changes in heart and kidney, so as to achieve early diagnosis and early intervention of cardiorenal syndrome, and improve the effect of disease diagnosis and treatment. At present, domestic and foreign scholars have studied and applied more markers mainly in renal tubular injury, including neutrophil gelatinase-associated lipocalin, kidney injury molecule-1 and urinary interleukin-18. In addition, other studies have found cell cycle arrest inducing factors, such as insulin-like growth factor binding protein 7, tissue inhibitor metallo proteinase-2, and fibroblast growth factor 23 associated with mineral metabolism. The increase of the content of these biomarkers in the body is earlier than the rise of serum creatinine, which can better predict the occurrence of early cardiorenal syndrome, and has a high application value and research value. After summarization of the biomarkers relating to type I and Ⅱ cardiorenal syndrome in domestic and foreign literatures, the research progress of several representative markers were reviewed to provide reference for related research.
